ritanserin has been researched along with Aniridia in 1 studies
Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.
ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.
Aniridia: A congenital abnormality in which there is only a rudimentary iris. This is due to the failure of the optic cup to grow. Aniridia also occurs in a hereditary form, usually autosomal dominant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aniridia is a panocular inherited rare eye disease linked to heterozygous mutations on the PAX6 gene, which fail to properly produce sufficient protein essential for normal eye development and function." | 5.62 | Ritanserin, a potent serotonin 2A receptor antagonist, represses MEK/ERK signalling pathway to restore PAX6 production and function in aniridia-like cellular model. ( Aberdam, D; Bremond-Gignac, D; Dorot, O; Frank, E; Oved, K; Pichinuk, E; Roux, LN; Zennaro, L; Zerbib, J, 2021) |
| "Aniridia is a panocular inherited rare eye disease linked to heterozygous mutations on the PAX6 gene, which fail to properly produce sufficient protein essential for normal eye development and function." | 1.62 | Ritanserin, a potent serotonin 2A receptor antagonist, represses MEK/ERK signalling pathway to restore PAX6 production and function in aniridia-like cellular model. ( Aberdam, D; Bremond-Gignac, D; Dorot, O; Frank, E; Oved, K; Pichinuk, E; Roux, LN; Zennaro, L; Zerbib, J, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oved, K | 1 |
| Zennaro, L | 1 |
| Dorot, O | 1 |
| Zerbib, J | 1 |
| Frank, E | 1 |
| Roux, LN | 1 |
| Bremond-Gignac, D | 1 |
| Pichinuk, E | 1 |
| Aberdam, D | 1 |
1 other study available for ritanserin and Aniridia
| Article | Year |
|---|---|
Ritanserin, a potent serotonin 2A receptor antagonist, represses MEK/ERK signalling pathway to restore PAX6 production and function in aniridia-like cellular model.
Topics: Aniridia; Cell Line; Cell Movement; Cell Proliferation; Drug Repositioning; Epithelium, Corneal; Gen | 2021 |